U.S. market Closed. Opens in 17 hours 25 minutes

TSVT | 2seventy bio, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 1.6750 - 1.9500
52 Week Range 1.5350 - 16.17
Beta 1.55
Implied Volatility 355.57%
IV Rank 88.10%
Day's Volume 770,095
Average Volume 1,921,779
Shares Outstanding 50,624,600
Market Cap 98,211,724
Sector Healthcare
Industry Biotechnology
IPO Date 2021-11-03
P/E Ratio -0.51
Forward P/E Ratio N/A
EPS -3.77
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 425
Country USA
Website TSVT
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
*Chart delayed
Analyzing fundamentals for TSVT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see TSVT Fundamentals page.

Watching at TSVT technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on TSVT Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙